ISSN: 2574-187X
Authors: Yao Fu, Yan Pang
Meibomian gland dysfunction (MGD) is a chronic inflammation-related disease, which can cause instability of tear film, discomfort of the ocular surface and eyelids, and finally lead to dry eye disease (DED). The current clinical therapy has the following disadvantages, such as time-consuming, general treatment effect, and expensive treatment. Nanomedicine has been used in the treatment of some ocular surface diseases. For example, nanoparticles have been used in some eye drops formulations as well as eye patches, which can enhance the water solubility of the drugs, prolong the action time, and reduce the toxicity. In this review, we have introduced MGD and its’ current clinical therapy. Since nanomedicine has already participated in treating DED patients and got satisfactory outcome, we believe that it will also have promising prospects in treating MGD.
Keywords: Inflammatory; Nanomedicine; Meibomian Gland Dysfunction
